Dr. Daniel J Renouf, MD
Claim this profileBC Cancer - Vancouver
Studies Pancreatic Cancer
Studies Gastroesophageal Junction Adenocarcinoma
7 reported clinical trials
15 drugs studied
Area of expertise
1Pancreatic Cancer
Stage III
Stage IV
2Gastroesophageal Junction Adenocarcinoma
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Daniel J Renouf, MD is currently running
Atezolizumab
for Cancer
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer. This is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 200 participants. Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). In the first stage for each cohort, 8 participants will be enrolled and if no participants respond to treatment, enrollment to that cohort will be closed. If 1 or more participants respond to treatment, up to 16 additional participants will be enrolled to that cohort. Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.
Recruiting1 award Phase 210 criteria
Glucose Monitoring
for Pancreatic Cancer
This study will investigate whether or not it is feasible to closely monitor and manage glucose levels in people with pancreatic cancer. It will also investigate what impact glucose management may have on pancreatic cancer. This is a pilot study that will use continuous glucose monitors (CGM) to monitor glucose levels in approximately 50 participants with pancreatic cancer. Participants will receive standard chemotherapy with a combination of up to four drugs to treat their pancreatic cancer: oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin (FOLFIRINOX). To treat high glucose levels, participants will be randomly assigned to one of two groups: Group 1 will receive anti-hyperglycemic treatment as guided by an endocrinologist with the aim of maintaining glucose levels between 4 and 10 mmol/L; Group 2 will receive anti-hyperglycemic treatment if their glucose levels are above 15 mmol/L, which is standard care. Participants in both Groups 1 and 2 will receive standard anti-hyperglycemic treatments: metformin, insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, sodium glucose co-transporter (SGLT2) inhibitors, and dipeptidyl peptidase 4 (DPP-4) inhibitors. After 4 cycles of FOLFIRINOX, the CGM will be removed but any anti-hyperglycemic treatments will continue as needed. If participants discontinue treatment with FOLFIRINOX, they will continue to be followed for survival and subsequent anti-cancer therapy and will continue follow-up for glucose-related concerns at the discretion of their endocrinologist and/or medical oncologist.
Recruiting1 award N/A10 criteria
More about Daniel J Renouf, MD
Clinical Trial Related4 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Daniel J Renouf, MD has experience with
- Tumour DNA And Proteins
- Anti-hyperglycemic Treatments (Metformin, Insulin, GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors)
- Continuous Glucose Monitor (CGM)
- CFI-402257
- BMS-986253
- Ipilimumab
Breakdown of trials Daniel J Renouf, MD has run
Pancreatic Cancer
Gastroesophageal Junction Adenocarcinoma
High Blood Sugar
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel J Renouf, MD specialize in?
Daniel J Renouf, MD focuses on Pancreatic Cancer and Gastroesophageal Junction Adenocarcinoma. In particular, much of their work with Pancreatic Cancer has involved Stage III patients, or patients who are Stage IV.
Is Daniel J Renouf, MD currently recruiting for clinical trials?
Yes, Daniel J Renouf, MD is currently recruiting for 3 clinical trials in Vancouver British Columbia. If you're interested in participating, you should apply.
Are there any treatments that Daniel J Renouf, MD has studied deeply?
Yes, Daniel J Renouf, MD has studied treatments such as Tumour DNA and Proteins, Anti-hyperglycemic Treatments (Metformin, Insulin, GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors), Continuous Glucose Monitor (CGM).
What is the best way to schedule an appointment with Daniel J Renouf, MD?
Apply for one of the trials that Daniel J Renouf, MD is conducting.
What is the office address of Daniel J Renouf, MD?
The office of Daniel J Renouf, MD is located at: BC Cancer - Vancouver, Vancouver, British Columbia V5Z 4E6 Canada. This is the address for their practice at the BC Cancer - Vancouver.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.